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Abstract Amyloids are a class of protein with unique self-aggregation properties, and their
aberrant accumulation can lead to cellular dysfunctions associated with neurodegenerative
diseases. While genetic and environmental factors can influence amyloid formation, molecular
triggers and/or facilitators are not well defined. Growing evidence suggests that non-identical
amyloid proteins may accelerate reciprocal amyloid aggregation in a prion-like fashion. While
humans encode ~30 amyloidogenic proteins, the gut microbiome also produces functional
amyloids. For example, curli are cell surface amyloid proteins abundantly expressed by certain gut
bacteria. In mice overexpressing the human amyloid a-synuclein (aSyn), we reveal that colonization
with curli-producing Escherichia coli promotes aSyn pathology in the gut and the brain. Curli
expression is required for E. coli to exacerbate aSyn-induced behavioral deficits, including intestinal
and motor impairments. Purified curli subunits accelerate aSyn aggregation in biochemical assays,
while oral treatment of mice with a gut-restricted amyloid inhibitor prevents curli-mediated
acceleration of pathology and behavioral abnormalities. We propose that exposure to microbial
amyloids in the gastrointestinal tract can accelerate aSyn aggregation and disease in the gut and
the brain.
Introduction
The accumulation and aggregation of amyloid proteins occurs during many neurodegenerative dis-
eases. Synucleinopathies are one family of amyloid disease, which includes Parkinson’s disease (PD),
Lewy Body disease (LBD), and Multiple System Atrophy (MSA). Central to their pathogenesis is the
accumulation of the neuronal protein a-Synuclein (aSyn) into insoluble amyloid aggregations, which
ultimately leads to inflammation and neuronal dysfunction (Jucker and Walker, 2013;
Brettschneider et al., 2015). aSyn aggregation can contribute to the death of dopaminergic neu-
rons in specific brain regions, resulting in motor symptoms (Poewe et al., 2017). Clinical and epide-
miological data suggest that accumulation of aSyn aggregates may first occur at peripheral sites,
such as the olfactory epithelium or gastrointestinal (GI) tract, before spreading to the brain
(Braak et al., 2003). Individuals diagnosed with various synucleinopathies often display constipation
Sampson et al. eLife 2020;9:e53111. DOI: https://doi.org/10.7554/eLife.53111 1 of 19
RESEARCH ARTICLE
and other GI dysfunctions years prior to the onset of movement dysfunction (Verbaan et al., 2007;
Colosimo, 2011; Engen et al., 2017; Mertsalmi et al., 2017; Sakakibara et al., 2019). Experimen-
tal evidence exists for a prion-like spread of aSyn aggregates (Woerman et al., 2015), including
propagation from the gut to the brain via the vagus nerve and/or spinal cord in rodent models
(Holmqvist et al., 2014; Uemura et al., 2018; Van Den Berge et al., 2019). In humans, recent epi-
demiological studies suggest an association between truncal vagotomy and appendectomy with a
decreased risk of PD (Svensson et al., 2015; Liu et al., 2017; Killinger et al., 2018), and in
increased risk of comorbidity with inflammatory bowel disease (IBD) (Hui et al., 2018; Peter et al.,
2018). While a role for protein aggregation and/or inflammation in the gut represents an emerging
area of research in synucleinopathies, the GI tract has been implicated in other neurological disor-
ders such as autism spectrum disorder, depression, anxiety and Alzheimer’s disease (Vuong et al.,
2017).
The gut is colonized with a complex microbiome that impacts development and function of the
immune, metabolic and nervous systems (Fung et al., 2017). Enterobacteriaceae, highly prevalent
within the gut of humans, can produce functional amyloid proteins termed curli (Tursi and Tu¨kel,
2018). Curli fibers are formed by bacterial secretion of an unfolded amyloid, CsgA, that subse-
quently aggregates extracellularly to form biofilms, mediate adhesion to epithelial cells, and are
involved in bacteriophage defense (Tursi and Tu¨kel, 2018; Vidakovic et al., 2018). Exposure to curli
not only modulates host inflammatory responses within the intestinal tract and periphery
(Gallo et al., 2015; Chen et al., 2016; Tursi and Tu¨kel, 2018), but oral administration of curli-pro-
ducing bacteria can also increase production and aggregation of the amyloid protein aSyn in aged
rats and nematodes (Chen et al., 2016). Biochemical studies demonstrate that native, bacterial
chaperones of curli are capable of transiently interacting with aSyn and modulating its aggregation
(Chorell et al., 2015; Evans et al., 2015). Interestingly, diverse human amyloid proteins including
aSyn, amyloid beta (Ab), cellular prion protein (PrPC), and Tau can accelerate the amyloidogenesis of
heterologous mammalian amyloid proteins (Clinton et al., 2010; Brettschneider et al., 2015;
Katorcha et al., 2017). Lesions containing mixed human amyloids have been observed in neurode-
generative brains (Rahimi and Kovacs, 2014; Spires-Jones et al., 2017), implicating interactions
between different amyloidogenic proteins in resulting pathology. Accordingly, we wondered
whether a bacterial amyloid protein can contribute to heterologous aggregation of mammalian aSyn
in the gut and the brain, leading to synucleinopathy-related behaviors.
Herein, we reveal that mono-colonization of aSyn-overexpressing mice with curli-producing
Escherichia coli exacerbates motor impairment and GI dysfunction, and promotes aSyn aggregation
and inflammation in the gut and brain. Enrichment of curli-producing E. coli to mice harboring a
healthy human microbiome is sufficient to aggravate aSyn-dependent pathophysiology. The purified
amyloidogenic subunit of curli fibers (CsgA) is sufficient to accelerate aSyn aggregation during in
vitro biochemical assays and pathophysiology in mice following intra-intestinal administration, while
variants of CsgA that are unable to form amyloids have no effect on aSyn aggregation. Oral treat-
ment of mice with a gut-restricted amyloid inhibitor reduces csgA expression in the gut, limits aSyn
aggregation in the brain, and alleviates GI and motor deficits in mice that overexpress aSyn. These
data provide novel insights into a trans-kingdom interaction between the gut microbiome and mam-
malian amyloids, and suggest the possibility that carriage of particular bacterial taxa may be a factor
that can exacerbate neurologic disease.
Results and discussion
Mono-colonization with curli-producing gut bacteria enhances aSyn
pathophysiology
We previously identified that depletion of the microbiome reduces pathophysiology in Thy1-aSyn
mice (alpha-synuclein overexpressing; ASO mice) (Sampson et al., 2016), which overexpress wild-
type human aSyn. Due to accumulation and aggregation of neuronal aSyn, mice display increased
neuroinflammation, GI dysfunction, and progressive motor abnormalities (Rockenstein et al., 2002;
Chesselet et al., 2012; Wang et al., 2012) that are relevant in the study of synucleinopathies. Prior
findings in germ-free Thy1-aSyn mice suggest that an unidentified member(s) of the gut microbiome
may be pathogenic in this mouse model (Sampson et al., 2016). Interestingly, increased colonization
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and mucosal association with Enterobacteriaceae, such as E. coli, have been reported in individuals
with PD compared to healthy controls (Forsyth et al., 2011), as well as a positive association of
Enterobacteriaceae abundance with disease severity (Scheperjans et al., 2015; Li et al., 2017).
To establish whether E. coli promotes aSyn-dependent motor dysfunction, we mono-associated
germ-free (GF) wild-type and ASO mice with the curli-producing E. coli strain MC4100, or Bacter-
oides fragilis strain NCTC9343 and segmented filamentous bacteria (SFB), which do not produce
curli. E. coli exacerbated the aSyn-dependent motor defects in ASO animals across a battery of
tests, compared to the other taxa (Figure 1A–F and Figure 1—figure supplement 1A–E). To deter-
mine the contribution of curli amyloids, we compared mice mono-colonized with wild-type E. coli
(WT) to those mono-colonized with an isogenic mutant lacking genes encoding the curli biosynthesis
machinery (DcsgBAC) (Wang and Chapman, 2008). Evaluation of coordinated motor function
revealed that colonization with the curli-deficient strain did not elicit robust motor impairment
(Figure 1A–F). We did not observe curli-dependent alterations to colonization levels or mucosal
association, despite detecting csgA expression (Figure 1—figure supplement 1F–I). In addition, the
curli-deficient mutant did not display alterations to lipopolysaccharide potency or structure (Fig-
ure 1—figure supplement 1J,K). Thus, curli-producing bacteria are capable of enhancing motor
deficits in ASO mice.
ASO mice colonized with curli-producing bacteria displayed increased aSyn fibril reactivity and
detergent-insoluble aSyn in the midbrain compared to mice with the DcsgBAC strain, despite similar
transgene production (Figure 1—figure supplement 2A–D,F,G). Histological and western blot anal-
ysis revealed increased phospho-serine129 aSyn (pS129-aSyn) deposition in the substantia nigra
(SN) of ASO mice, indicative of pathological aSyn aggregation, (Figure 1G,H, and Figure 1—figure
supplement 2E,H,J). Further, mice colonized with WT E. coli show increased proteinase K-resistant
aSyn inclusions in the midbrain (Figure 1I and Figure 1—figure supplement 2I), with little alteration
to pS129-aSyn in the frontal cortex (Figure 1—figure supplement 2K,L). Additionally, we observed
increased pS129-aSyn in the proximal large intestine, and elevated aSyn fibril reactivity in the duo-
denum and proximal large intestine of ASO mice mono-colonized with curli-producing E. coli (Fig-
ure 1—figure supplement 2M–P). Previous research has shown that synuclein pathology,
neuroinflammation, and motor defects occur at early ages in the ASO mouse model without con-
comitant loss of striatal dopamine, tyrosine hydroxylase positive (TH+) neurons in the midbrain, or
loss of neurons in the myenteric plexus (Fleming et al., 2004; Lam et al., 2011; Chesselet et al.,
2012; Wang et al., 2012). Consistent with these prior observations, we do not observe decreases in
total striatal dopamine, midbrain TH expression, TH+ neurons, nor myenteric PGP9.5+ neurons,
under the colonization conditions and ages assessed, suggesting pathology and motor deficits are
independent of dopamine or neuron loss (Figure 1, figure supplement S2Q-S).
Mono-colonization of ASO mice with curli-producing E. coli resulted in increased expression of
the proinflammatory cytokines interleukin 6 (IL-6) and tumor necrosis factor alpha (TNFa) in brain-
derived CD11b+ cells, and increased cytokine production in the midbrain and striatum (Figure 1—
figure supplement 3A–C). In addition, Iba+ microglia morphologies indicated reduced activation in
ASO mice colonized with the curli-deficient strain (Figure 1—figure supplement 3D–G). Multiplexed
ELISA analysis revealed increased cytokine and chemokine production in colonic tissue of mice
mono-colonized with curli-producing E. coli, irrespective of genotype (Figure 1—figure supplement
3H,J,K), and no noteworthy changes to serum cytokines of ASO mice based on colonization status
(Figure 1—figure supplement 3I). These data reveal that a bacterial amyloid from the gut micro-
biome can exacerbate pathology and inflammation, in both the gut and brain, in mice that overex-
press aSyn.
Curli biosynthesis within a complex microbiome contributes to motor
and GI deficits
To explore host-microbiome interactions in a more natural context, we tested whether introduction
of curli-producing bacteria to a healthy human microbiota is sufficient to enhance aSyn-dependent
pathophysiology. GF ASO mice were transplanted with fecal microbiota from a human donor pre-
dicted to contain low levels of csgA, as indicated by PICRUSt analysis following 16S rRNA sequenc-
ing (Figure 2—figure supplement 1A). This single microbiome was supplemented with either WT E.
coli or the DcsgBAC strain. Both strains reached similar abundances in the feces (Figure 2—figure
supplement 1B,C), while csgA expression and amyloid production appeared only in mice colonized
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with WT bacteria (Figure 2—figure supplement 1C–E). Mice harboring a microbiota containing WT
E. coli displayed significantly impaired motor and GI performance compared to animals with a com-
plex microbiota plus the curli-deficient strain (Figure 2A–G). Moreover, enrichment of curli-produc-
ing bacteria resulted in increased aSyn fibril reactivity in the midbrain and elevated pS129-aSyn
deposition in the SN, without changes to the number of TH+ neurons (Figure 2H and Figure 2—fig-
ure supplement 1F–J). Morphometric analysis of microglia demonstrated concomitant changes
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Figure 1. Mono-colonization with curli-producing gut bacteria enhances aSyn pathophysiology germ-free wild-type BDF1 (WT) and Thy1-aSyn (ASO)
mice were mono-colonized with wild-type E. coli MC4100 (WT) or an isogenic curli-deficient strain (DcsgBAC) at 5–6 weeks of age. Motor function was
assessed at 12–13 weeks of age by quantifying (A), beam traversal time, (B), pole descent time, (C), nasal adhesive removal time, (D), hindlimb clasping
score, (E), wirehang time. (F), Principal component analysis of compiled motor scores from tests in (A–E). Quantification of (G, H) pS129aSyn and (I)
proteinase K–resistant aSyn by immunofluorescence microscopy in the substantia nigra and midbrain. n = 13–16 (A–F), n = 4.5 (G–I). Points represent
individuals, bars represent the mean and standard error. Data analyzed by one-way ANOVA with Tukey post-hoc test (A–E), and two-tailed t-test for (G–
I). *p0.05; **p0.01; ***p0.001; ****p0.0001. Motor data are compiled from three independent cohorts.
The online version of this article includes the following source data and figure supplement(s) for figure 1:
Source data 1. Source data and statistical analysis.
Figure supplement 1. E. coli alters motor deficits, and CsgA does not influence colonization, inflammatory capacity, or dopamine production Germ-
free (GF) wild-type (WT) or Thy1- aSyn (ASO) mice were mono-colonized with either Bacteroides fragilis (Bfrag), segmented filamentous bacteria (SFB),
or Escherichia coli (Ecoli).
Figure supplement 1—source data 1. Source data and statistical analysis.
Figure supplement 2. Mono-colonization with curli-sufficient bacteria induce increased aSyn-dependent pathology Germ-free (GF) wild-type (WT) or
Thy1-aSyn (ASO) animals were mono-colonized with curli-sufficient E. coli (WT) or curli-deficient E. coli (DcsgBAC).
Figure supplement 2—source data 1. Source data and statistical analysis.
Figure supplement 3. Mono-colonization with curli-sufficient bacteria induces altered inflammatory responses in the brain and intestine.
Figure supplement 3—source data 1. Source data and statistical analysis.
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indicative of inflammatory status in the midbrain (Figure 2—figure supplement 1K–N). Therefore,
in the context of a complex human microbiota, curli-producing E. coli are sufficient to modulate
aSyn-mediated pathophysiology.
The bacterial amyloid protein, CsgA, accelerates aSyn fibrilization
Emerging data suggest that non-orthologous amyloid proteins can accelerate heterologous
aggregation (Clinton et al., 2010; Brettschneider et al., 2015; Katorcha et al., 2017). We there-
fore tested whether CsgA can directly impact aggregation of aSyn. Purified monomeric CsgA accel-
erated production of aSyn aggregates during in vitro biochemical amyloid assays (Figure 3A–C and
Figure 3—figure supplement 1A), even at concentrations below which CsgA self-aggregates
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Figure 2. Curli biosynthesis within a complex microbiome contributes to motor and GI deficits Germ-free Thy1-aSyn (ASO) mice were colonized with
fecal microbes derived from healthy human at 5–6 weeks of age, and concurrently supplemented with either wild-type E. coli MC4100 (+WT) or a curli-
deficient strain (+DcsgBAC). Motor function was tested longitudinally at 12, 15, and 20 weeks of age in the (A) beam traversal, (B) pole descent, (C)
adhesive removal, (D) hindlimb clasping score, (E) wirehang tests. (F) Principal component analysis of compiled motor scores from tests in (A–E). (G)
Fecal output over a 15-min period observed at week 21 of age. Quantification of (H) pS129aSyn by immunofluorescence microscopy in the substantia
nigra. n = 12 (A–F), n = 6 (G), n = 4 (H). Data points represent individuals, bars represent the mean and standard error. Time courses analyzed by two-
way ANOVA, with Sidak post-hoc test for between group comparisons indicated above individual time points, and brackets indicating significance
between colonization status. Data in (H) analyzed two-tailed t-test. *p0.05; **p0.01; ***p0.001; ****p0.0001. Motor data are compiled from two
independent cohorts.
The online version of this article includes the following source data and figure supplement(s) for figure 2:
Source data 1. Source data and statistical analysis.
Figure supplement 1. Amyloid-producing bacteria in humanized animals modulate microglia responses.
Figure supplement 1—source data 1. Source data and statistical analysis.
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(Figure 3D). The aSyn fibrils purified from these reactions maintained an ability to accelerate aSyn
amyloidogenesis (Figure 3—figure supplement 1B,C), suggesting that CsgA-induced aSyn aggre-
gates are propagation-competent, similar to other amyloids (Spires-Jones et al., 2017). Surprisingly,
we could not detect a direct interaction between purified CsgA and aSyn monomers by surface plas-
mon resonance (Figure 3—figure supplement 1D), perhaps indicating transient interactions or
requirements for prior oligomerization of either or both proteins. Unlike aSyn, Tau aggregation was
not accelerated by CsgA (Figure 3—figure supplement 1E–G). Native amyloid-forming properties
of CsgA are required, as a non-amyloidogenic form of CsgA (CsgA:Q49A/N54A/Q139A/N144A;
‘SlowGo’ Wang and Chapman, 2008) did not augment aSyn aggregation in vitro (Figure 3—figure
supplement 2A–C). To investigate the dependence of these amyloidogenic residues in vivo, we
mono-colonized ASO mice with E. coli producing either wild-type CsgA or CsgA:SlowGo proteins
(Wang and Chapman, 2008). Motor performance in ASO mice harboring SlowGo-producing E. coli
was less severe in comparison to mice colonized with WT bacteria (Figure 3—figure supplement
2D–H), although not to the extent of the DcsgBAC strain, qualitatively (see Figure 1).
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Figure 3. The bacterial amyloid protein, CsgA, accelerates aSyn fibrilization In vitro biophysical analysis with
purified aSyn and CsgA proteins. (A) Aggregation as measured by Thioflavin T fluorescence over time during
aSyn amyloid formation alone or in the presence of CsgA monomers (25:1 molar ratio). Time to reach (B)
exponential fibrilization/lag phase and (C) half-maximum from reactions in (A). (D) Representative transmission
electron micrographs of aSyn or CsgA alone, or in combination, at 0 and 60 hr post-aggregation. n = 3 (A–C). Bars
represent the mean and standard error. Data are analyzed by two-tailed, t-test. **p0.01; ***p0.001.
The online version of this article includes the following source data and figure supplement(s) for figure 3:
Source data 1. Source data and statistical analysis.
Figure supplement 1. CsgA seeds aSyn aggregation and propagation in vitro.
Figure supplement 1—source data 1. Source data and statistical analysis.
Figure supplement 2. CsgA seeds aSyn aggregation in vitro and in vivo through native amyloidogenic properties.
Figure supplement 2—source data 1. Source data and statistical analysis.
Figure supplement 3. Intestinal injection of amyloidogenic curli promotes progressive motor dysfunction.
Figure supplement 3—source data 1. Source data and statistical analysis.
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Next, a peptide spanning the aggregation domain of CsgA or a non-amyloidogenic version
(N122A) (Tu¨kel et al., 2009) were injected directly into the intestinal wall of SPF ASO mice. Intra-
intestinal delivery of amyloidogenic CsgA peptide, but not the mutant peptide, resulted in progres-
sive motor and GI dysfunction (Figure 3—figure supplement 3A–G). Furthermore, increased aSyn
fibrils were detected in the midbrains of amyloidogenic peptide-injected animals (Figure 3—figure
supplement 3H). We conclude that gut exposure to a bacterial amyloid is sufficient to exacerbate
motor deficits and aSyn brain pathology in this mouse model, in a manner dependent on CsgA
aggregation.
Curli-driven pathophysiology in mice requires functional amyloid
formation
Epigallocatechin gallate (EGCG) is a plant-derived, dietary polyphenol that physically inhibits amy-
loid formation, including aSyn aggregation (Bieschke et al., 2010). EGCG is also capable of block-
ing CsgA amyloidogenesis and represses csgA transcript expression in E. coli through activation of
specific stress response pathways within the bacterial cell (Serra et al., 2016). We reveal here that
EGCG treatment did not impair E. coli growth in culture, but significantly reduced biofilm formation,
a process dependent on the production and assembly of curli (Figure 4—figure supplement 1A,
B) (Tursi and Tu¨kel, 2018). Additionally, EGCG also inhibited CsgA-accelerated aSyn amyloid for-
mation during in vitro biochemical aggregation assays (Figure 4A). Notably, EGCG remains largely
gut-restricted in rodents and humans and is not readily bioavailable in circulation or brain tissues fol-
lowing oral administration (Lambert et al., 2003; Lin et al., 2007; Cai et al., 2018). Oral treatment
of wild-type E. coli mono-colonized ASO mice with EGCG did not affect fecal E. coli abundance, but
resulted in decreased csgA production (Figure 4B and Figure 4—figure supplement 1C). Assess-
ment of motor performance revealed that EGCG improved both motor and GI defects exacerbated
by curli-producing E. coli in ASO mice (Figure 4C–I and Figure 4—figure supplement 1D–I). In
addition, oral EGCG administration reduced aSyn aggregation and pS129-aSyn deposition in both
the striatum and midbrain (Figure 4J and Figure 4—figure supplement 1J–M). Furthermore, micro-
glia morphological changes were limited in EGCG-treated mice (Figure 4—figure supplement 1O–
R). In addition to its ability to directly inhibit aggregation of bacterial and host-derived amyloids,
EGCG has antioxidant and anti-inflammatory activities (Li et al., 2004) that may also contribute to
the rescue of CsgA-accelerated, aSyn-dependent pathophysiology. Collectively, these data reveal
that curli is a specific bacterial structure that can accelerate mammalian amyloid aggregation in vitro
and in vivo.
Conclusion
The majority of synucleinopathy incidences are idiopathic, with multifactorial and complex risks that
contribute to disease initiation and/or progression (Ritz et al., 2016; Soldner et al., 2016;
Johnson et al., 2019). Our findings reveal that the bacterial amyloid CsgA can accelerate aSyn
aggregation and enhance motor abnormalities in mice that are genetically predisposed to aSyn
pathology. Curli production in the gut of non-susceptible mice does not impair motor performance
at the timepoints examined, suggesting that this microbial trigger is not sufficient, but rather
requires additional predisposing factors to promote disease outcomes. Further, inhibiting amyloid
formation in the gut correlates with improvements in curli-induced behaviors and pathology. Our
study does not reconcile how curli production within the gastrointestinal tract ultimately manifests
aSyn aggregation in the brain. Experimental evidence exists for a prion-like spread of aSyn aggre-
gates (Woerman et al., 2015), including propagation from the gut to the midbrain via the vagus
nerve and/or spinal cord in rodent models (Uemura et al., 2018; Kim et al., 2019; Van Den Berge
et al., 2019), although evidence for sustained propagation from the GI tract to structures outside
the brainstem in primates is currently lacking (Manfredsson et al., 2018). Epidemiological studies
suggest an association between full truncal vagotomy with a decreased risk of PD (Svensson et al.,
2015). Intriguingly, there appears to be a positive correlation between inflammatory bowel disease
and neurodegenerative disease (Hui et al., 2018; Peter et al., 2018). In experimental models, induc-
tion of GI inflammation, for instance through LPS or dextran sodium sulfate administration, is suffi-
cient to induce aSyn pathology in the CNS (Choi et al., 2018; Kishimoto et al., 2019; Perez-
Pardo et al., 2019). Aggregates of both CsgA and aSyn are capable of signaling through the innate
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immune receptor Toll-like receptor 2 (TLR2) leading to increased inflammatory responses
(Tu¨kel et al., 2009; Poewe et al., 2017). In fact, inhibiting TLR2 in aSyn-based mouse models leads
to improved pathology and motor outcomes (Kim et al., 2015; Kim et al., 2018). Our data demon-
strate curli-dependent increases of inflammatory markers in both the intestine and brain, as well as
acceleration of aSyn pathology, but do not determine which of these may be the primary driver of
curli-mediated pathophysiology. Disentangling these complex relationships in future studies will
define how pathologic signals from bacterial amyloids are transduced from the gut to the brain, via
transneuronal spread of aSyn aggregates and/or an inflammatory cascade, and mechanisms of gut-
to-brain signaling that contribute to motor impairment.
Synucleinopathy is linked to marked changes to the structure of the microbiome. Numerous stud-
ies have reported microbiome differences in persons with PD compared to unaffected individuals
(Hasegawa et al., 2015; Keshavarzian et al., 2015; Scheperjans et al., 2015; Unger et al., 2016;
Bedarf et al., 2017; Hill-Burns et al., 2017; Hopfner et al., 2017; Li et al., 2017; Barichella et al.,
2019; Lin et al., 2018); however, examination of the gut microbiome during other
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Figure 4. Curli-driven pathophysiology in mice requires functional amyloid formation. (A), Representative in vitro aSyn aggregation measured by
Thioflavin T fluorescence during aSyn amyloid formation alone or in the presence of CsgA (25:1 molar ratio), with and without EGCG (50 mM)
treatment. (B–H) Germ-free Thy1-aSyn mice (ASO) were mono-colonized with WT E. coli at 5–6 weeks of age, and given water alone (Vehicle: Veh) or
treated with EGCG ad lib in drinking water (+EGCG). (B) RNA was extracted from fecal pellets and csgA expression quantified by qRT-PCR, relative to
rrsA. Motor function was assessed at 15–16 weeks of age by quantifying (C) beam traversal time, (D) pole descent time, (E) nasal adhesive removal time,
(F) hindlimb clasping score, (G) wirehang tests. (H) Principal component analysis of compiled motor scores from tests in (C–G). (I) Fecal output over a 15
min period. (J) Quantification of insoluble aSyn fibrils in the ventral midbrain by dot blot assay. n = 8 (B); n = 10–11 (C–G); n = 4–5 (I, J). Points
represent individuals, bars represent the mean and standard error. Data analyzed by two-tailed Mann-Whitney for B–G, (J) and two-way ANOVA with
Sidek’s post-hoc test for I with between group comparisons indicated above individual time points, and brackets indicating significance between
treatment status. *p0.05; **p0.01; ***p0.001; ****p0.0001. Motor data compiled from two independent cohorts.
The online version of this article includes the following source data and figure supplement(s) for figure 4:
Source data 1. Source data and statistical analysis.
Figure supplement 1. Inhibition of functional amyloid formation dampens progressive pathophysiology.
Figure supplement 1—source data 1. Source data and statistical analysis.
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synucleinopathies, such as MSA or LBD are still in their infancy (Engen et al., 2017). Some reports
have identified the family Enterobacteriaceae as enriched in PD compared to unaffected individuals
(Unger et al., 2016; Li et al., 2017; Barichella et al., 2019). In those studies which performed corre-
lation analysis between disease severity and microbiome composition, enrichment of Enterobacteria-
ceae is observed to be positively associated with worsened motor symptoms (Scheperjans et al.,
2015; Li et al., 2017). To our knowledge, no study to date has identified differential abundance of
csgA or curli-encoding genes specifically in human incidences, and only a single study to date has
utilized metagenomic sequencing of the gut microbiome during PD (Bedarf et al., 2017). Despite
recent advances defining microbiome changes in neurodegenerative diseases, a contributing role by
gut bacteria to synucleinopathies in humans remains correlative (reviewed in Sampson, 2019). In
experimental models, however, transplant of fecal microbiomes from PD patients into ASO mice
results in greater motor deficits than microbiomes from healthy controls (Sampson et al., 2016),
suggesting functional consequences to changes in gut microbial composition.
Although our findings herein are limited to a single transgenic animal mouse model, and similar
pathologies are observed in aged rats and nematodes (Chen et al., 2016), it is possible that these
observations are model specific. Non-amyloid contributions from diverse gut bacteria are also likely
to occur and influence neurodegenerative outcomes. For instance, enrichment of the gut bacterium
Proteus mirabilis, or intestinal administration of its purified LPS, impairs the dopaminergic system of
mice and increases susceptibility to neurotoxins (Choi et al., 2018). Infection with Gram-negative
bacteria, including Citrobacter sp. (a taxonomic relative of E. coli), can trigger a pathological process
leading to neurodegenerative immune responses in the brain and loss of midbrain dopamine pro-
duction in a PD-relevant mouse model (Matheoud et al., 2019). In addition, specific microbiome-
derived metabolites promote microglia maturation (Erny et al., 2015) and enhance aSyn-dependent
pathology in germ-free mice (Sampson et al., 2016). Conversely, specific microbial metabolites
(Blacher et al., 2019) or fecal microbiome transplants (Sun et al., 2018) may provide protection
from neurodegenerative insults.
While CsgA is one example of bacterially-produced amyloid, microbial amyloid formation in gen-
eral may influence physiological processes with outcomes relevant for neurodegenerative disease
(Friedland and Chapman, 2017). For example, the Pseudomonas sp. functional amyloid, FapC, may
also accelerate aSyn aggregation in vitro (Christensen et al., 2019), and bacterial chaperones of
CsgA modulate aSyn amyloidogenesis (Evans et al., 2015). More broadly, CsgA is observed to
accelerate amyloid b aggregation in vitro (Hartman et al., 2013; Perov et al., 2019), as well as the
disease-associated amyloids, islet amyloid polypeptide (IAPP) and semen enhancer of viral infection
(SEVI) in vitro (Hartman et al., 2013), and serum amyloid A in mice (Lundmark et al., 2005). Emerg-
ing evidence in diverse animal models suggests that gut bacteria may modulate amyloid-driven dis-
eases, not only in synucleinopathy as we and others describe, but Alzheimer’s disease
(Harach et al., 2017; Dodiya et al., 2019) and amyotrophic lateral sclerosis (ALS) as well
(Blacher et al., 2019), providing justification for future human studies and revealing possible new
targets for interventions that may prevent, slow, or halt amyloid formation and neurodegenerative
disease.
Materials and methods
Key resources table
Reagent type
(species) or
resource Designation
Source or
reference Identifiers
Additional
information
Strain, strain
background
(Mus musculus)
Thy1- alpha-
synuclein
(Line 61),
BDF1 background
Rockenstein
et al., 2002
ASO (alpha-
synuclein over-
expressing)
With permission,
UCSD
Strain, strain
background
(Escherichia coli)
Str. K12,
MC4100
Zhou et al., 2013 WT (wild-type)
Continued on next page
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Continued
Reagent type
(species) or
resource Designation
Source or
reference Identifiers
Additional
information
Strain, strain
background
(Escherichia coli)
Str. K12,
MC4100:DcsgBAC
Zhou et al., 2013 DcsgBAC
Strain
(Escherichia coli)
Str. K12, MC4100:
CsgA:Q49A/N54A/
Q139A/N144A
Wang and
Chapman, 2008
SlowGo
Antibody Anti-alpha
synuclein,
mouse monoclonal
BD Cat#: 610787 (1:1000)
Antibody Anti-pS129
alpha-synuclein,
rabbit monoclonal
AbCam Cat#: Ab51253 (1:1000)
Antibody Anti-tyrosine
hydroxylase,
mouse monoclonal
Millipore Cat#: MAB318 (1:1000)
Antibody Anti-Iba1, rabbit Wako Cat#: 019–19741 (1:1000)
Antibody Anti-aggregated
alpha-synuclein,
rabbit polyclonal
AbCam Cat#:
MJFR-14-6-4-2
(1:1000)
Antibody Anti-mouse
IgG-546,
goat polyclonal
Life Technologies Cat#: A-11003 (1:1000)
Antibody Anti-rabbit
IgG-546,
goat polyclonal
Life Technologies Cat#: A-11010 (1:1000)
Antibody Anti-mouse
IgG-488, goat
polyclonal
Life Technologies Cat#: A-11001 (1:1000)
Antibody Anti-rabbit
IgG-HRP,
goat polyclonal
Cell Signaling Cat#: 7074 (1:1000)
Peptide,
recombinant
protein
CsgA
(N’-QYGGNN-C’)
Bio-Synthesis,
Inc; Tu¨kel et al., 2009
CsgA
Peptide,
recombinant
protein
N122A
(N’QYGGNA-C’)
Bio-Synthesis,
Inc; Tu¨kel et al., 2009
N122A
Sequence-
based reagent
16S rRNA:
5’-TCCTACGGGAG
GCAGCAGT-3’ and
5’-GGACTACCAGGG
TATCTAATCCTGTT-3’
IDT qPCR primer PrimerBank
Sequence-
based reagent
rrsA:
5’-AGTGATAAACTG
GAGGAGGTG-3‘ and
5’-GGACTACGACG
CACTTTATGAG-3’
IDT qPCR primer PrimerBank
Sequence-
based reagent
csgA:
5’-ATGACGGTTAA
ACAGTTCGG-3’ and
5’-AGGAGTTAGAT
GCAGTCTGG-3’
IDT qPCR primer PrimerBank
Sequence-
based reagent
gapdh:
5’-CATGGCCTTCC
GTGTTCCTA-3’ and
5’-CCTGCTTCACCA
CCTTCTTGAT-3’
IDT qPCR primer PrimerBank
Continued on next page
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Continued
Reagent type
(species) or
resource Designation
Source or
reference Identifiers
Additional
information
Sequence-
based reagent
il6:
5’-TAGTCCTTCCTA
CCCCAATTTCC-3’ and
5’-TTGGTCCTTAGC
CACTCCTTC-3’,
IDT qPCR primer PrimerBank
Sequence-
based reagent
TH:
5’-CCAAGGTTCAT
TGGACGGC-3’ and
5’-CTCTCCTCGAAT
ACCACAGCC-3’
IDT qPCR primer PrimerBank
Sequence-
based reagent
tnfa;
5’-CCCTCACACTCA
GATCATCTTCT-3’ and
5’-GCTACGACAG
TGGGCTACAG-3’
IDT qPCR primer PrimerBank
Animals
Male wild-type and Thy1-aSyn mice (Line 61, with permission from University of California, San
Diego) were generated as described previously (Rockenstein et al., 2002; Chesselet et al., 2012;
Sampson et al., 2016), through breeding female BDF1 background Thy1-aSyn mice to male BDF1
offspring generated via crossing female C57BL/6 with DBA/2 males (Charles River, Hollister, CA),
and refreshing breeding pairs ~ 6 months. Germ-free (GF) Thy1-aSyn breeding pairs were generated
via caesarian section and cross-fostered by GF Swiss-Webster dams. Conventionally colonized and
mono-colonized animals were housed in autoclaved, ventilated, microisolator caging. GF animals
were housed in open-top caging within flexible film isolators and maintained microbiologically ster-
ile, confirmed via 16S rRNA PCR from fecal-derived DNA and culture of fecal pellets on Brucella
blood agar or tryptic soy blood agar (Teknova, Hollister, CA) under anaerobic and aerobic condi-
tions, respectively. Mono-colonized animals received ~108 cfu of the indicated bacterial strains
in ~100 mL sodium bicarbonate buffer (5% w/v) at 5–6 weeks of age. Human microbiome colonized
animals received ~100 mL 0.1 g/mL fecal extract from previously sampled healthy human donor (ENA
Accession: PRJEB17694; Sample #: 10483.donor2.HC; MMA_008 [Sampson et al., 2016], California
Institute of Technology’s Institutional Review Board #15–0568- exempt), at 5–6 weeks of age. For
mice mono-colonized with E. coli containing plasmid vectors for CsgA and CsgA:SlowGo, drinking
water was supplemented with 50 mg/mL kanamycin (Sigma Aldrich, St Louis, MO). Human micro-
biome colonized mice were associated with WT or DcsgBAC mutant E. coli at time of microbiota
transplant. For epigallocatechin gallate (EGCG) treatment, animals received filter-sterilized EGCG
(Sigma Aldrich) at 200 mg/mL in drinking water ad libitum beginning at 5–6 weeks of age. All animals
received autoclaved food (LabDiet Laboratory Autoclavable Diet 5010, St Louis, MO) and water ad
libitum, were maintained on the same 12 hr light-dark cycle, and housed in the same room of the
facility. All animal husbandry and experiments were approved by the California Institute of Technol-
ogy’s Institutional Animal Care and Use Committee (IACUC), through protocol #1707.
Motor function assessment
Motor function was assessed similarly to previous studies (Fleming et al., 2004; Sampson et al.,
2016), between hours 7 and 9 of the light phase, within a biosafety cabinet. Beam traversal and pole
descent were performed first, followed by fecal output measurement. One day later, wirehang,
adhesive removal and hindlimb scoring was performed. Beam traversal- A 1 m plexiglass beam con-
sisting of four segments of 0.25 m in length (Stark’s Plastics, Forest Park, OH) was constructed with
consecutively thinner widths of 3.5, 2.5, 1.5, and 0.5 cm, with 1 cm overhangs placed 1 cm below
the surface of the beam and the narrowest end placed into home cage. Animals were trained for
two consecutive days before the first testing. On the first day of training, animals received one trial
with the home cage positioned close to the widest segment, where the animal was placed, and
guided the animals forward along the narrowing beam. Animals received two more trials with limited
or no assistance to encourage forward movement and stability on the beam. On the seccond day of
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training, animals were given three trials to traverse the beam, with little to no assistance. On the
third day, animals were timed over three trials to traverse from the widest segment to the home
cage. Time was measured from the placement of the animal’s forelimbs onto the second segment
until a forelimb reached the home cage. Score was averaged over three trials. Pole descent- A 0.5 m
long pole, 1 cm in diameter, wrapped with non-adhesive shelf liner to facilitate the animals grip, was
placed into the home cage, with animals removed and placed into fresh housing. Animals received 2
days of training to descend from the top of the pole and into the home cage. On the first day, ani-
mals received three trials to descend the pole. First animals were placed head-down ~1/3 the dis-
tance above the base, the second trial from ~2/3 the height, and on the third trial animals were
placed at the top of the pole, head-down. The second day of training, animals were tasked with
descending, head-down, from the top of the pole, three times. On the day of testing, animals were
placed head-down on the top of the pole and timed beginning when the experimenter released the
animal and ended when one hind-limb was placed on the pole base. Score was averaged over three
trials. Adhesive removal- ¼” round adhesive labels (Avery, Glendale, CA) were placed on the nasal
bridge. Animals were placed into their home cage (with cage mates removed into separate cage)
and timed to completely remove the sticker. Animals were recorded over two trials, and averaged.
Hindlimb clasping reflex scoring- Animals were gently lifted by the mid-section of the tail and
observed over ~5–10 s (Zhang et al., 2014). Animals were assigned a score of 0, 1, 2, or 3. 0 was
scored to animals that freely moved both their limbs and extended them outwards. A 1 was assigned
to animals which clasped one hindlimb inward for the duration of the restraint or if both legs exhib-
ited partial inward clasping. 2 was given if both legs clasped inward for the majority of the observa-
tion, but still exhibited some flexibility. A score of 3 was assigned if animals displayed complete
rigidity of hindlimbs that immediately clasped inward and exhibited no signs of flexibility. For ani-
mals in Figure 3—figure supplement 2G, animals were scored twice on 2 consecutive days and the
score averaged, the remainder were scored once. Wirehang- Animals were placed in the center of a
30 cm by 30 cm screen with 1 cm wide mesh. The screen was inverted head-over-tail and placed on
supports ~ 40 cm above an open cage with deep bedding. Animals were timed until they released
their grip or remained for 60 s, and the score from two trials averaged. Fecal Output- Animals were
removed from their home cages and placed into a 12 cm x 25 cm translucent cylinder. Fecal pellets
were counted every 5 min, cumulative over 15 min. Principal component analysis- PCA was per-
formed using ClustVis web tool, with default settings and reversed axis for display (Metsalu and
Vilo, 2015).
Bacterial strains, manipulations, and characterizations
Escherichia coli K12 str. MC4100 and the previously characterized isogenic deletion mutant of the
csgBAC operon were cultured aerobically in YESCA media at 37˚C (Zhou et al., 2013). Biofilm assays
were performed via crystal violet staining of static culture at room temperature in YESCA as
described previously (Zhou et al., 2013). Congo red staining was performed on YESCA agar follow-
ing 2–3 days growth at room temperature as described previously (Zhou et al., 2013). Fecal bacte-
rial DNA was isolated using QuickDNA Fecal/Soil Microbe Miniprep (Zymo Research, Irvine, CA).
Fecal bacterial RNA was isolated using PowerMicrobiome RNA Isolation kit (MoBio, Carlsbad, CA)
and cDNA generated via iScript cDNA Synthesis kit (BioRad, Hercules, CA). qPCR was performed
with SybrGreen master mix (Applied Biosystems, Foster City, CA) on an AB7900ht instrument using
the following primers: 16 s rRNA-5’-TCCTACGGGAGGCAGCAGT-3’ and 5’-GGACTACCAGGGTA
TCTAATCCTGTT-3’; rrsA-5’-AGTGATAAACTGGAGGAGGTG- ‘and 5’-GGACTACGACGCACTTTA
TGAG-3’; csgA- 5’-ATGACGGTTAAACAGTTCGG-3’ and 5’-AGGAGTTAGATGCAGTCTGG-3’. Bac-
teroides fragilis str. NTCT9343 was cultured anaerobically in brain-heart infusion (BHI) broth at 37˚C,
and colonized into GF animals via oral gavage of ~108 cfu in 100 mL sodium bicarbonate buffer (5%
w/v) at 5–6 weeks of age. Segmented filamentous bacteria were colonized via bedding transfer and
co-housing within a mono-associated gnotobiotic isolator. Colonization was confirmed by PCR for
SFB 16 s RNA. For growth curves, E. coli was first grown aerobically at 37˚C overnight in BHI broth,
and subcultured at 1:400 in BHI containing indicated concentrations of EGCG, in a 200 mL volume in
a 96-well plate. Plates were incubated at 37˚C aerobically, with orbital shaking in a BioTek Cytation 5
plate reader, and the optical density at 600 nm measured every hour. Endotoxin content was mea-
sured following overnight growth at 37˚C, aerobically in BHI using the Pierce LAL Chromogenic
Endotoxin kit (ThermoFisher, Pittsburgh, PA) according to manufacturer’s instructions. LPS was
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stained from lysates derived from identically grown bacterial cultures following separation on a 4–
20% SDS-PAGE gel with Pro-Q Emerald 300 LPS stain kit (ThermoFisher), according to manufac-
turer’s instructions.
a-Synuclein aggregation assays
Thioflavin T (ThT) assays-Freshly purified CsgA (both wild-type and ‘SlowGo’) and aSyn were diluted
in 50 mM KPi (pH 7.3) to the molar concentrations indicated in each experiment. Samples were incu-
bated in 96-well, black, flat bottom plates at 37˚C with 20 mM ThT and 100 mM NaCl under continu-
ous shaking conditions, along with a 1 mm glass bead for homogenous mixing. The ThT
fluorescence intensity was recorded in 30 min interval using a Tecan plate reader (excitation: 438
nm; emission: 495 nm; cut-off: 475 nm). TauK18 aggregation assay- 50 mM of TauK18 fragment with
heparin (TauK18:Heparin 4:1) was incubated with or without CsgA (2 mM) in 14 mM MES buffer pH
6.8 at 37˚C with continuous shaking in 96-well, black, flat bottom plates. 2 mm beads and 20 mM
ThT was added to all the wells. The ThT fluorescence was monitored with previously mentioned
parameters after 30 min in FLUOstar omega plate reader (BMG Labtech). Transmission electron
microscopy- Aliquots of CsgA and aSyn reactions were taken at indicated timepoints. Five microli-
ters of sample was applied on glow-discharged carbon-coated grids, incubated for 1 min and
washed with MilliQ water before staining with 1% uranyl acetate. Samples were imaged on Jeol elec-
tron microscope (JEOL-1400 plus). Circular dichroism spectroscopy- aSyn alone or with CsgA (in 20
mM KPi pH 7.3) were analyzed using a Jasco J-810 spectropolarimeter from 190 nm to 250 nm at
25˚C immediately after purification and at indicated timepoints.
Synuclein pathology and inflammatory responses
CD11b enrichment- Animals were sedated with pentobarbital and perfused; whole brains were
homogenized in PBS via passage through a 100 mm mesh filter, myelin debris were removed using
magnetic separation with Myelin Removal Beads (Miltenyi Biotec, San Diego, CA), and subsequently
CD11b positive enrichment performed similarly, via Microglia Microbeads (Miltenyi Biotec), accord-
ing to manufacturer’s instructions. Cells were immediately lysed in Trizol and RNA extracted with the
DirectZol RNA extraction (Zymo Research). cDNA and qPCR performed as described above with pri-
mers- gapdh: 5’-CATGGCCTTCCGTGTTCCTA-3’ and 5’-CCTGCTTCACCACCTTCTTGAT-3’; il6: 5’-
TAGTCCTTCCTACCCCAATTTCC-3’ and 5’-TTGGTCCTTAGCCACTCCTTC-3’, tyrosine hydroxylase:
5’-CCAAGGTTCATTGGACGGC-3’ and 5’-CTCTCCTCGAATACCACAGCC-3’; and tnfa; 5’-CCCTCA-
CACTCAGATCATCTTCT-3’ and 5’-gctacgacagtgggctacag-3’. Synuclein imaging- Perfused whole
brains were dissected and fixed with 4% (w/v) paraformaldehyde. 50 mm sections were generated
via vibratome. For proteinase-K resistant staining, free-floating sections were treated briefly with 5
mg/mL proteinase K (NEB, Ipswich, MA) and stained with anti-alpha synuclein (1:1000 mouse;
#610787 BD, Franklin Lakes, NJ), pS129-synuclein staining utilized anti-pS129syn (1:1000 rabbit;
#ab51253 AbCam, Cambridge, UK) and anti-tyrosine hydroxylase (1:1000 mouse; MAB318, Milli-
pore, Burlington, MA). Sections were stained with secondary anti-mouse IgG-AF488 (1:1000, Life
Technologies, Carlsbad, CA), anti-rabbit IgG-546 (1:1000, Life Technologies) and Neurotrace (Life
Technologies), mounted with ProFade Diamond DAPI (Life Technologies) and imaged with a 20x
objective on a Zeiss LSM800 confocal microscope. Sections corresponding to ~1500 mm from midline
were counted manually for TH+ cell bodies and pS129syn puncta in ImageJ software. Microglia
reconstructions- Microglia were imaged and analyzed as previously described (Erny et al., 2015;
Sampson et al., 2016). Thin sections prepared as above were stained with anti-Iba1 (1:1000 rabbit,
Wako, Richmond, VA) and anti-rabbit IgG-AF546 (1:1000, Life Technologies). Z-stacks were imaged
at 1 mm steps and analyzed using Imaris software. ELISAs- For TNFa and IL6 (eBioscience, San
Diego, CA), aSyn (ThermoFisher), and dopamine (Eagle Biosciences, Nashua, NH) tissue homoge-
nates were prepared in RIPA buffer containing protease inhibitor (ThermoFisher), and ELISA per-
formed according to manufacturer’s instructions with 100 mg of tissue. Multiplexed intestine (100 mg)
and serum cytokine levels were measured on a Bio-Plex 200 using the Bio-Plex Mouse Cytokine 23-
plex Assay (Biorad) according to manufacturer’s instructions. Dot blot- Tissue homogenates were
spotted onto 0.45 mm nitrocellulose membranes, in 1 mg/mL aliquots. Membranes were blocked with
5% dry skim milk in Tris-buffered saline and stained with anti-aggregated alpha-synuclein antibody
(1:1000, MJFR-14-6-4-2, rabbit, AbCam) and anti-rabbit IgG-HRP (1:1000, Cell Signaling Technology,
Sampson et al. eLife 2020;9:e53111. DOI: https://doi.org/10.7554/eLife.53111 13 of 19
Research article Microbiology and Infectious Disease Neuroscience
Danvers, MA), and detected with Clarity chemiluminescence substrate (BioRad) on a BioRad GelDoc
XR and densitometry performed.
Intestinal injections
Synthetic hexapeptides of CsgA (Nterm-QYGGNN-Cterm) and the non-amyloidogenic mutant
N122A (Nterm-QYGGNA-Cterm) were purchased from Bio-Synthesis Inc (Lewisville, TX). Mice were
anesthetized with isoflurane (1–4% vol/vol) and kept on a self-regulating heating pad throughout the
procedure. A 10 ml Hamilton syringe fitted with a 36-gauge beveled needle was loaded with 30 mg
of either hexapeptide in saline (9 ml total). Each animal was injected in three locations (both sides of
pyloric antrum and duodenum [0.5 cm past the pyloric sphincter]; 3 ml each location) by inserting the
needle tip bevel facing up into the intestine wall at a 15˚ angle. After injection, the abdominal mus-
cle/peritoneal layer and skin were sutured separately, then mice returned to home cages. Mice were
injected subcutaneously with buprenorphine SR (1 mg/kg) and monitored for 3 days for normal food
and water consumption.
Statistics and data availability
Data were analyzed in GraphPad Prism, with the analysis indicated in each figure legend. Statistical
output and numerical source data presented within the manuscript are available within the supple-
mentary information included with this manuscript.
Acknowledgements
We thank Drs. E Hsiao, M Sampson, S Campbell, D Yamashita, D Donabedian, and members of the
SKM laboratory for helpful critiques and review of this manuscript. We are grateful to J Paramo, S
Estrada, K Ly and the Caltech OLAR staff for animal care husbandry, and Y Garcia-Flores (Caltech)
for technical support. Electron micrographs of amyloids were generated at the Microscopy and
Imaging Analysis Laboratory Core at the University of Michigan. Fluorescent imaging and image
analysis were performed in the Caltech Biological Imaging Facility, with the support of the Caltech
Beckman Institute and the Arnold and Mabel Beckman Foundation. TRS was a Larry L Hillblom Foun-
dation postdoctoral fellow. This project was supported by funds from the Heritage Medical Research
Institute to VG and SKM; the Knut and Alice Wallenberg Foundation and Swedish Research Council
to PW-S; the National Institutes of Health grants AG054101 (CC), GM118651 (MRC) and NS085910
(SKM); Axial Biotherapeutics to SKM; and the Department of Defense grant PD160030 to SKM.
Additional information
Competing interests
Timothy R Sampson: has intellectual property pending in relationship to the content of this manu-
script, US Patent App. 15/893,456 and 16/302,321. Matthew Chapman: a member of the Scientific
Advisory Board of Axial Biotherapeutics. Sarkis K Mazmanian: has financial interest in Axial Biothera-
peutics. Has intellectual property pending in relationship to the content of this manuscript, US Pat-
ent App. 15/893,456 and 16/302,321. The other authors declare that no competing interests exist.
Funding
Funder Grant reference number Author
Larry L. Hillblom Foundation Timothy R Sampson
Heritage Medical Research In-
stitute
Viviana Gradinaru
Sarkis K Mazmanian
Knut och Alice Wallenbergs
Stiftelse
Pernilla Wittung-Stafshede
Swedish Research Council Pernilla Wittung-Stafshede
National Institute on Aging AG054101 Collin Challis
Sampson et al. eLife 2020;9:e53111. DOI: https://doi.org/10.7554/eLife.53111 14 of 19
Research article Microbiology and Infectious Disease Neuroscience
National Institute of General
Medical Sciences
GM118651 Matthew Chapman
National Institute of Neurolo-
gical Disorders and Stroke
NS085910 Sarkis K Mazmanian
Department of Defense PD160030 Sarkis K Mazmanian
Axial Biotherapeutics Sarkis K Mazmanian
The funders had no role in study design, data collection and interpretation, or the
decision to submit the work for publication.
Author contributions
Timothy R Sampson, Conceptualization, Investigation, Visualization; Collin Challis, Neha Jain, Anas-
tasiya Moiseyenko, Mark S Ladinsky, Istvan Horvath, Investigation, Visualization; Gauri G Shastri, Brit-
tany D Needham, Investigation; Taren Thron, Resources, Investigation; Justine W Debelius, Stefan
Janssen, Formal analysis; Rob Knight, Viviana Gradinaru, Supervision; Pernilla Wittung-Stafshede,
Matthew Chapman, Sarkis K Mazmanian, Conceptualization, Supervision
Author ORCIDs
Timothy R Sampson https://orcid.org/0000-0002-2486-8766
Stefan Janssen https://orcid.org/0000-0003-0955-0589
Pernilla Wittung-Stafshede https://orcid.org/0000-0003-1058-1964
Viviana Gradinaru http://orcid.org/0000-0001-5868-348X
Sarkis K Mazmanian https://orcid.org/0000-0003-2713-1513
Ethics
Animal experimentation: All animal husbandry and experiments were approved by the California
Institute of Technology’s Institutional Animal Care and Use Committee (IACUC) under protocol
#1707.
Decision letter and Author response
Decision letter https://doi.org/10.7554/eLife.53111.sa1
Author response https://doi.org/10.7554/eLife.53111.sa2
Additional files
Supplementary files
. Transparent reporting form
Data availability
All data generated or analysed during this study are included in the manuscript and supporting files.
Source data files and statistical output for all figures have been provided.
References
Barichella M, Severgnini M, Cilia R, Cassani E, Bolliri C, Caronni S, Ferri V, Cancello R, Ceccarani C, Faierman S,
Pinelli G, Bellis G, Zecca L, Cereda E, Consolandi C, Pezzoli G. 2019. Unraveling gut Microbiota in Parkinson’s
disease and atypical parkinsonism. Movement Disorders 34:396–405. DOI: https://doi.org/10.1002/mds.27581
Bedarf JR, Hildebrand F, Coelho LP, Sunagawa S, Bahram M, Goeser F, Bork P, Wu¨llner U. 2017. Functional
implications of microbial and viral gut metagenome changes in early stage L-DOPA-naı¨ve parkinson’s disease
patients. Genome Medicine 9:39. DOI: https://doi.org/10.1186/s13073-017-0428-y, PMID: 28449715
Bieschke J, Russ J, Friedrich RP, Ehrnhoefer DE, Wobst H, Neugebauer K, Wanker EE. 2010. EGCG remodels
mature alpha-synuclein and amyloid-beta fibrils and reduces cellular toxicity. PNAS 107:7710–7715.
DOI: https://doi.org/10.1073/pnas.0910723107, PMID: 20385841
Blacher E, Bashiardes S, Shapiro H, Rothschild D, Mor U, Dori-Bachash M, Kleimeyer C, Moresi C, Harnik Y, Zur
M, Zabari M, Brik RB-Z, Kviatcovsky D, Zmora N, Cohen Y, Bar N, Levi I, Amar N, Mehlman T, Brandis A, et al.
Sampson et al. eLife 2020;9:e53111. DOI: https://doi.org/10.7554/eLife.53111 15 of 19
Research article Microbiology and Infectious Disease Neuroscience
2019. Potential roles of gut microbiome and metabolites in modulating ALS in mice. Nature 572:474–480.
DOI: https://doi.org/10.1038/s41586-019-1443-5
Braak H, Ru¨b U, Gai WP, Del Tredici K. 2003. Idiopathic Parkinson’s disease: possible routes by which vulnerable
neuronal types may be subject to neuroinvasion by an unknown pathogen. Journal of Neural Transmission 110:
517–536. DOI: https://doi.org/10.1007/s00702-002-0808-2, PMID: 12721813
Brettschneider J, Del Tredici K, Lee VM, Trojanowski JQ. 2015. Spreading of pathology in neurodegenerative
diseases: a focus on human studies. Nature Reviews Neuroscience 16:109–120. DOI: https://doi.org/10.1038/
nrn3887, PMID: 25588378
Cai Z-Y, Li X-M, Liang J-P, Xiang L-P, Wang K-R, Shi Y-L, Yang R, Shi M, Ye J-H, Lu J-L, Zheng X-Q, Liang Y-R.
2018. Bioavailability of tea catechins and its improvement. Molecules 23:2346. DOI: https://doi.org/10.3390/
molecules23092346
Chen SG, Stribinskis V, Rane MJ, Demuth DR, Gozal E, Roberts AM, Jagadapillai R, Liu R, Choe K, Shivakumar B,
Son F, Jin S, Kerber R, Adame A, Masliah E, Friedland RP. 2016. Exposure to the functional bacterial amyloid
protein curli enhances Alpha-Synuclein aggregation in aged Fischer 344 rats and Caenorhabditis elegans.
Scientific Reports 6:34477. DOI: https://doi.org/10.1038/srep34477, PMID: 27708338
Chesselet MF, Richter F, Zhu C, Magen I, Watson MB, Subramaniam SR. 2012. A progressive mouse model of
Parkinson’s disease: the Thy1-aSyn ("Line 61") mice. Neurotherapeutics 9:297–314. DOI: https://doi.org/10.
1007/s13311-012-0104-2, PMID: 22350713
Choi JG, Kim N, Ju IG, Eo H, Lim SM, Jang SE, Kim DH, Oh MS. 2018. Oral administration of Proteus mirabilis
damages dopaminergic neurons and motor functions in mice. Scientific Reports 8:1275. DOI: https://doi.org/
10.1038/s41598-018-19646-x, PMID: 29352191
Chorell E, Andersson E, Evans ML, Jain N, Go¨theson A, A˚den J, Chapman MR, Almqvist F, Wittung-Stafshede P.
2015. Bacterial chaperones CsgE and CsgC differentially modulate human a-Synuclein amyloid formation via
transient contacts. PLOS ONE 10:e0140194. DOI: https://doi.org/10.1371/journal.pone.0140194, PMID: 26465
894
Christensen LFB, Jensen KF, Nielsen J, Vad BS, Christiansen G, Otzen DE. 2019. Reducing the amyloidogenicity
of functional amyloid protein FapC increases its ability to inhibit a-Synuclein fibrillation. ACS Omega 4:4029–
4039. DOI: https://doi.org/10.1021/acsomega.8b03590, PMID: 31459612
Clinton LK, Blurton-Jones M, Myczek K, Trojanowski JQ, LaFerla FM. 2010. Synergistic interactions between A ,
Tau, and -Synuclein: Acceleration of Neuropathology and Cognitive Decline. Journal of Neuroscience 30:7281–
7289. DOI: https://doi.org/10.1523/JNEUROSCI.0490-10.2010
Colosimo C. 2011. Nonmotor presentations of multiple system atrophy. Nature Reviews Neurology 7:295–298.
DOI: https://doi.org/10.1038/nrneurol.2011.5, PMID: 21343894
Dodiya HB, Kuntz T, Shaik SM, Baufeld C, Leibowitz J, Zhang X, Gottel N, Zhang X, Butovsky O, Gilbert JA,
Sisodia SS. 2019. Sex-specific effects of microbiome perturbations on cerebral ab amyloidosis and microglia
phenotypes. The Journal of Experimental Medicine 216:1542–1560. DOI: https://doi.org/10.1084/jem.
20182386, PMID: 31097468
Engen PA, Dodiya HB, Naqib A, Forsyth CB, Green SJ, Voigt RM, Kordower JH, Mutlu EA, Shannon KM,
Keshavarzian A. 2017. The potential role of Gut-Derived inflammation in multiple system atrophy. Journal of
Parkinson’s Disease 7:331–346. DOI: https://doi.org/10.3233/JPD-160991, PMID: 28234259
Erny D, Hrabeˇ de Angelis AL, Jaitin D, Wieghofer P, Staszewski O, David E, Keren-Shaul H, Mahlakoiv T,
Jakobshagen K, Buch T, Schwierzeck V, Utermo¨hlen O, Chun E, Garrett WS, McCoy KD, Diefenbach A, Staeheli
P, Stecher B, Amit I, Prinz M. 2015. Host Microbiota constantly control maturation and function of microglia in
the CNS. Nature Neuroscience 18:965–977. DOI: https://doi.org/10.1038/nn.4030, PMID: 26030851
Evans ML, Chorell E, Taylor JD, A˚den J, Go¨theson A, Li F, Koch M, Sefer L, Matthews SJ, Wittung-Stafshede P,
Almqvist F, Chapman MR. 2015. The bacterial curli system possesses a potent and selective inhibitor of
amyloid formation. Molecular Cell 57:445–455. DOI: https://doi.org/10.1016/j.molcel.2014.12.025,
PMID: 25620560
Fleming SM, Salcedo J, Fernagut PO, Rockenstein E, Masliah E, Levine MS, Chesselet MF. 2004. Early and
progressive sensorimotor anomalies in mice overexpressing wild-type human alpha-synuclein. Journal of
Neuroscience 24:9434–9440. DOI: https://doi.org/10.1523/JNEUROSCI.3080-04.2004, PMID: 15496679
Forsyth CB, Shannon KM, Kordower JH, Voigt RM, Shaikh M, Jaglin JA, Estes JD, Dodiya HB, Keshavarzian A.
2011. Increased intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin
exposure markers in early Parkinson’s disease. PLOS ONE 6:e28032. DOI: https://doi.org/10.1371/journal.
pone.0028032, PMID: 22145021
Friedland RP, Chapman MR. 2017. The role of microbial amyloid in neurodegeneration. PLOS Pathogens 13:
e1006654. DOI: https://doi.org/10.1371/journal.ppat.1006654, PMID: 29267402
Fung TC, Olson CA, Hsiao EY. 2017. Interactions between the Microbiota, immune and nervous systems in health
and disease. Nature Neuroscience 20:145–155. DOI: https://doi.org/10.1038/nn.4476, PMID: 28092661
Gallo PM, Rapsinski GJ, Wilson RP, Oppong GO, Sriram U, Goulian M, Buttaro B, Caricchio R, Gallucci S, Tu¨kel
C¸. 2015. Amyloid-DNA composites of bacterial biofilms stimulate autoimmunity. Immunity 42:1171–1184.
DOI: https://doi.org/10.1016/j.immuni.2015.06.002, PMID: 26084027
Harach T, Marungruang N, Duthilleul N, Cheatham V, Mc Coy KD, Frisoni G, Neher JJ, Fa˚k F, Jucker M, Lasser T,
Bolmont T. 2017. Reduction of abeta amyloid pathology in APPPS1 transgenic mice in the absence of gut
Microbiota. Scientific Reports 7:41802. DOI: https://doi.org/10.1038/srep41802, PMID: 28176819
Sampson et al. eLife 2020;9:e53111. DOI: https://doi.org/10.7554/eLife.53111 16 of 19
Research article Microbiology and Infectious Disease Neuroscience
Hartman K, Brender JR, Monde K, Ono A, Evans ML, Popovych N, Chapman MR, Ramamoorthy A. 2013.
Bacterial curli protein promotes the conversion of PAP 248-286 into the amyloid SEVI: cross-seeding of dissimilar
amyloid sequences . PeerJ 1:e5. DOI: https://doi.org/10.7717/peerj.5
Hasegawa S, Goto S, Tsuji H, Okuno T, Asahara T, Nomoto K, Shibata A, Fujisawa Y, Minato T, Okamoto A,
Ohno K, Hirayama M. 2015. Intestinal dysbiosis and lowered serum Lipopolysaccharide-Binding protein in
Parkinson’s Disease. PLOS ONE 10:e0142164. DOI: https://doi.org/10.1371/journal.pone.0142164
Hill-Burns EM, Debelius JW, Morton JT, Wissemann WT, Lewis MR, Wallen ZD, Peddada SD, Factor SA, Molho
E, Zabetian CP, Knight R, Payami H. 2017. Parkinson’s disease and Parkinson’s disease medications have
distinct signatures of the gut microbiome. Movement Disorders 32:739–749. DOI: https://doi.org/10.1002/
mds.26942, PMID: 28195358
Holmqvist S, Chutna O, Bousset L, Aldrin-Kirk P, Li W, Bjo¨rklund T, Wang ZY, Roybon L, Melki R, Li JY. 2014.
Direct evidence of parkinson pathology spread from the gastrointestinal tract to the brain in rats. Acta
Neuropathologica 128:805–820. DOI: https://doi.org/10.1007/s00401-014-1343-6, PMID: 25296989
Hopfner F, Ku¨nstner A, Mu¨ller SH, Ku¨nzel S, Zeuner KE, Margraf NG, Deuschl G, Baines JF, Kuhlenba¨umer G.
2017. Gut Microbiota in parkinson disease in a northern german cohort. Brain Research 1667:41–45.
DOI: https://doi.org/10.1016/j.brainres.2017.04.019, PMID: 28506555
Hui KY, Fernandez-Hernandez H, Hu J, Schaffner A, Pankratz N, Hsu N-Y, Chuang L-S, Carmi S, Villaverde N, Li
X, Rivas M, Levine AP, Bao X, Labrias PR, Haritunians T, Ruane D, Gettler K, Chen E, Li D, Schiff ER, et al. 2018.
Functional variants in the LRRK2 gene confer shared effects on risk for Crohn’s disease and Parkinson’s disease
. Science Translational Medicine 10:eaai7795. DOI: https://doi.org/10.1126/scitranslmed.aai7795
Johnson ME, Stecher B, Labrie V, Brundin L, Brundin P. 2019. Triggers, facilitators, and aggravators: redefining
Parkinson’s Disease Pathogenesis. Trends in Neurosciences 42:4–13. DOI: https://doi.org/10.1016/j.tins.2018.
09.007
Jucker M, Walker LC. 2013. Self-propagation of pathogenic protein aggregates in neurodegenerative diseases.
Nature 501:45–51. DOI: https://doi.org/10.1038/nature12481, PMID: 24005412
Katorcha E, Makarava N, Lee YJ, Lindberg I, Monteiro MJ, Kovacs GG, Baskakov IV. 2017. Cross-seeding of
prions by aggregated a-synuclein leads to transmissible spongiform encephalopathy. PLOS Pathogens 13:
e1006563. DOI: https://doi.org/10.1371/journal.ppat.1006563, PMID: 28797122
Keshavarzian A, Green SJ, Engen PA, Voigt RM, Naqib A, Forsyth CB, Mutlu E, Shannon KM. 2015. Colonic
bacterial composition in Parkinson’s disease. Movement Disorders 30:1351–1360. DOI: https://doi.org/10.
1002/mds.26307, PMID: 26179554
Killinger BA, Madaj Z, Sikora JW, Rey N, Haas AJ, Vepa Y, Lindqvist D, Chen H, Thomas PM, Brundin P, Brundin
L, Labrie V. 2018. The vermiform appendix impacts the risk of developing Parkinson’s disease. Science
Translational Medicine 10:eaar5280. DOI: https://doi.org/10.1126/scitranslmed.aar5280, PMID: 30381408
Kim C, Rockenstein E, Spencer B, Kim HK, Adame A, Trejo M, Stafa K, Lee HJ, Lee SJ, Masliah E. 2015.
Antagonizing neuronal Toll-like receptor 2 prevents synucleinopathy by activating autophagy. Cell Reports 13:
771–782. DOI: https://doi.org/10.1016/j.celrep.2015.09.044, PMID: 26489461
Kim C, Spencer B, Rockenstein E, Yamakado H, Mante M, Adame A, Fields JA, Masliah D, Iba M, Lee HJ,
Rissman RA, Lee SJ, Masliah E. 2018. Immunotherapy targeting toll-like receptor 2 alleviates
neurodegeneration in models of synucleinopathy by modulating a-synuclein transmission and
neuroinflammation. Molecular Neurodegeneration 13:43. DOI: https://doi.org/10.1186/s13024-018-0276-2,
PMID: 30092810
Kim S, Kwon SH, Kam TI, Panicker N, Karuppagounder SS, Lee S, Lee JH, Kim WR, Kook M, Foss CA, Shen C,
Lee H, Kulkarni S, Pasricha PJ, Lee G, Pomper MG, Dawson VL, Dawson TM, Ko HS. 2019. Transneuronal
propagation of pathologic a-Synuclein from the gut to the brain models Parkinson’s Disease. Neuron 103:627–
641. DOI: https://doi.org/10.1016/j.neuron.2019.05.035, PMID: 31255487
Kishimoto Y, Zhu W, Hosoda W, Sen JM, Mattson MP. 2019. Chronic mild gut inflammation accelerates brain
neuropathology and motor dysfunction in a-Synuclein mutant mice. NeuroMolecular Medicine 21:239–249.
DOI: https://doi.org/10.1007/s12017-019-08539-5, PMID: 31079293
Lam HA, Wu N, Cely I, Kelly RL, Hean S, Richter F, Magen I, Cepeda C, Ackerson LC, Walwyn W, Masliah E,
Chesselet M-F, Levine MS, Maidment NT. 2011. Elevated tonic extracellular dopamine concentration and
altered dopamine modulation of synaptic activity precede dopamine loss in the striatum of mice
overexpressing human a-synuclein. Journal of Neuroscience Research 89:1091–1102. DOI: https://doi.org/10.
1002/jnr.22611
Lambert JD, Lee MJ, Lu H, Meng X, Hong JJ, Seril DN, Sturgill MG, Yang CS. 2003. Epigallocatechin-3-gallate is
absorbed but extensively glucuronidated following oral administration to mice. The Journal of Nutrition 133:
4172–4177. DOI: https://doi.org/10.1093/jn/133.12.4172, PMID: 14652367
Li R, Huang YG, Fang D, Le WD. 2004. Epigallocatechin Gallate inhibits lipopolysaccharide-induced microglial
activation and protects against inflammation-mediated dopaminergic neuronal injury. Journal of Neuroscience
Research 78:723–731. DOI: https://doi.org/10.1002/jnr.20315, PMID: 15478178
Li W, Wu X, Hu X, Wang T, Liang S, Duan Y, Jin F, Qin B. 2017. Structural changes of gut Microbiota in
Parkinson’s disease and its correlation with clinical features. Science China Life Sciences 60:1223–1233.
DOI: https://doi.org/10.1007/s11427-016-9001-4, PMID: 28536926
Lin LC, Wang MN, Tseng TY, Sung JS, Tsai TH. 2007. Pharmacokinetics of (-)-epigallocatechin-3-gallate in
conscious and freely moving rats and its brain regional distribution. Journal of Agricultural and Food Chemistry
55:1517–1524. DOI: https://doi.org/10.1021/jf062816a, PMID: 17256961
Sampson et al. eLife 2020;9:e53111. DOI: https://doi.org/10.7554/eLife.53111 17 of 19
Research article Microbiology and Infectious Disease Neuroscience
Lin A, Zheng W, He Y, Tang W, Wei X, He R, Huang W, Su Y, Huang Y, Zhou H, Xie H. 2018. Gut Microbiota in
patients with Parkinson’s disease in southern China. Parkinsonism & Related Disorders 53:82–88. DOI: https://
doi.org/10.1016/j.parkreldis.2018.05.007, PMID: 29776865
Liu B, Fang F, Pedersen NL, Tillander A, Ludvigsson JF, Ekbom A, Svenningsson P, Chen H, Wirdefeldt K. 2017.
Vagotomy and Parkinson disease: a swedish register-based matched-cohort study. Neurology 88:1996–2002.
DOI: https://doi.org/10.1212/WNL.0000000000003961, PMID: 28446653
Lundmark K, Westermark GT, Olse´n A, Westermark P. 2005. Protein fibrils in nature can enhance amyloid
protein A amyloidosis in mice: cross-seeding as a disease mechanism. PNAS 102:6098–6102. DOI: https://doi.
org/10.1073/pnas.0501814102, PMID: 15829582
Manfredsson FP, Luk KC, Benskey MJ, Gezer A, Garcia J, Kuhn NC, Sandoval IM, Patterson JR, O’Mara A,
Yonkers R, Kordower JH. 2018. Induction of alpha-synuclein pathology in the enteric nervous system of the rat
and non-human primate results in gastrointestinal dysmotility and transient CNS pathology. Neurobiology of
Disease 112:106–118. DOI: https://doi.org/10.1016/j.nbd.2018.01.008, PMID: 29341898
Matheoud D, Cannon T, Voisin A, Penttinen AM, Ramet L, Fahmy AM, Ducrot C, Laplante A, Bourque MJ, Zhu L,
Cayrol R, Le Campion A, McBride HM, Gruenheid S, Trudeau LE, Desjardins M. 2019. Intestinal infection
triggers parkinson’s disease-like symptoms in Pink1-/- mice. Nature 571:565–569. DOI: https://doi.org/10.1038/
s41586-019-1405-y, PMID: 31316206
Mertsalmi TH, Aho VTE, Pereira PAB, Paulin L, Pekkonen E, Auvinen P, Scheperjans F. 2017. More than
constipation - bowel symptoms in Parkinson’s disease and their connection to gut microbiota. European
Journal of Neurology 24:1375–1383. DOI: https://doi.org/10.1111/ene.13398
Metsalu T, Vilo J. 2015. ClustVis: a web tool for visualizing clustering of multivariate data using principal
component analysis and heatmap. Nucleic Acids Research 43:W566–W570. DOI: https://doi.org/10.1093/nar/
gkv468, PMID: 25969447
Perez-Pardo P, Dodiya HB, Engen PA, Forsyth CB, Huschens AM, Shaikh M, Voigt RM, Naqib A, Green SJ,
Kordower JH, Shannon KM, Garssen J, Kraneveld AD, Keshavarzian A. 2019. Role of TLR4 in the gut-brain Axis
in Parkinson’s disease: a translational study from men to mice. Gut 68:829–843. DOI: https://doi.org/10.1136/
gutjnl-2018-316844, PMID: 30554160
Perov S, Lidor O, Salinas N, Golan N, Tayeb-Fligelman E, Deshmukh M, Willbold D, Landau M. 2019. Structural
insights into curli CsgA Cross-b fibril architecture inspire repurposing of Anti-amyloid compounds as Anti-
biofilm agents. PLOS Pathogens 15:e1007978. DOI: https://doi.org/10.1371/journal.ppat.1007978, PMID: 3146
9892
Peter I, Dubinsky M, Bressman S, Park A, Lu C, Chen N, Wang A. 2018. Anti-Tumor necrosis factor therapy and
incidence of parkinson disease among patients with inflammatory bowel disease. JAMA Neurology 75:939–
946. DOI: https://doi.org/10.1001/jamaneurol.2018.0605, PMID: 29710331
Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, Schrag AE, Lang AE. 2017. Parkinson
disease. Nature Reviews Disease Primers 3:17013. DOI: https://doi.org/10.1038/nrdp.2017.13, PMID: 283324
88
Rahimi J, Kovacs GG. 2014. Prevalence of mixed pathologies in the aging brain. Alzheimer’s Research & Therapy
6:82. DOI: https://doi.org/10.1186/s13195-014-0082-1, PMID: 25419243
Ritz BR, Paul KC, Bronstein JM. 2016. Of pesticides and men: a California story of genes and environment in
Parkinson’s Disease. Current Environmental Health Reports 3:40–52. DOI: https://doi.org/10.1007/s40572-016-
0083-2, PMID: 26857251
Rockenstein E, Mallory M, Hashimoto M, Song D, Shults CW, Lang I, Masliah E. 2002. Differential
neuropathological alterations in transgenic mice expressing alpha-synuclein from the platelet-derived growth
factor and Thy-1 promoters. Journal of Neuroscience Research 68:568–578. DOI: https://doi.org/10.1002/jnr.
10231, PMID: 12111846
Sakakibara R, Doi H, Fukudo S. 2019. Lewy Body constipation. Journal of the Anus, Rectum and Colon 3:10–17.
DOI: https://doi.org/10.23922/jarc.2018-022, PMID: 31559362
Sampson TR, Debelius JW, Thron T, Janssen S, Shastri GG, Ilhan ZE, Challis C, Schretter CE, Rocha S, Gradinaru
V, Chesselet MF, Keshavarzian A, Shannon KM, Krajmalnik-Brown R, Wittung-Stafshede P, Knight R, Mazmanian
SK. 2016. Gut Microbiota regulate motor deficits and neuroinflammation in a model of Parkinson’s Disease.
Cell 167:1469–1480. DOI: https://doi.org/10.1016/j.cell.2016.11.018, PMID: 27912057
Sampson T. 2019. The impact of indigenous microbes on Parkinson’s Disease. Neurobiology of Disease 15:
104426. DOI: https://doi.org/10.1016/j.nbd.2019.03.014
Scheperjans F, Aho V, Pereira PA, Koskinen K, Paulin L, Pekkonen E, Haapaniemi E, Kaakkola S, Eerola-Rautio J,
Pohja M, Kinnunen E, Murros K, Auvinen P. 2015. Gut Microbiota are related to Parkinson’s disease and clinical
phenotype. Movement Disorders 30:350–358. DOI: https://doi.org/10.1002/mds.26069, PMID: 25476529
Serra DO, Mika F, Richter AM, Hengge R. 2016. The green tea polyphenol EGCG inhibits E. coli biofilm
formation by impairing amyloid curli fibre assembly and downregulating the biofilm regulator CsgD via the s(E)
-dependent sRNA RybB. Molecular Microbiology 101:136–151. DOI: https://doi.org/10.1111/mmi.13379,
PMID: 26992034
Soldner F, Stelzer Y, Shivalila CS, Abraham BJ, Latourelle JC, Barrasa MI, Goldmann J, Myers RH, Young RA,
Jaenisch R. 2016. Parkinson-associated risk variant in distal enhancer of a-synuclein modulates target gene
expression. Nature 533:95–99. DOI: https://doi.org/10.1038/nature17939, PMID: 27096366
Spires-Jones TL, Attems J, Thal DR. 2017. Interactions of pathological proteins in neurodegenerative diseases.
Acta Neuropathologica 134:187–205. DOI: https://doi.org/10.1007/s00401-017-1709-7, PMID: 28401333
Sampson et al. eLife 2020;9:e53111. DOI: https://doi.org/10.7554/eLife.53111 18 of 19
Research article Microbiology and Infectious Disease Neuroscience
Sun MF, Zhu YL, Zhou ZL, Jia XB, Xu YD, Yang Q, Cui C, Shen YQ. 2018. Neuroprotective effects of fecal
Microbiota transplantation on MPTP-induced parkinson’s disease mice: Gut microbiota, glial reaction and
TLR4/TNF-a signaling pathway. Brain, Behavior, and Immunity 70:48–60. DOI: https://doi.org/10.1016/j.bbi.
2018.02.005, PMID: 29471030
Svensson E, Horva´th-Puho´ E, Thomsen RW, Djurhuus JC, Pedersen L, Borghammer P, Sørensen HT. 2015.
Vagotomy and subsequent risk of Parkinson’s disease. Annals of Neurology 78:522–529. DOI: https://doi.org/
10.1002/ana.24448, PMID: 26031848
Tu¨kel C, Wilson RP, Nishimori JH, Pezeshki M, Chromy BA, Ba¨umler AJ. 2009. Responses to amyloids of
microbial and host origin are mediated through Toll-like receptor 2. Cell Host & Microbe 6:45–53. DOI: https://
doi.org/10.1016/j.chom.2009.05.020, PMID: 19616765
Tursi SA, Tu¨kel C¸agla. 2018. Curli-Containing enteric biofilms inside and out: matrix composition, immune
recognition, and disease implications. Microbiology and Molecular Biology Reviews 82:00028-18. DOI: https://
doi.org/10.1128/MMBR.00028-18
Uemura N, Yagi H, Uemura MT, Hatanaka Y, Yamakado H, Takahashi R. 2018. Inoculation of a-synuclein
preformed fibrils into the mouse gastrointestinal tract induces lewy body-like aggregates in the brainstem via
the vagus nerve. Molecular Neurodegeneration 13:21. DOI: https://doi.org/10.1186/s13024-018-0257-5,
PMID: 29751824
Unger MM, Spiegel J, Dillmann KU, Grundmann D, Philippeit H, Bu¨rmann J, Faßbender K, Schwiertz A, Scha¨fer
KH. 2016. Short chain fatty acids and gut Microbiota differ between patients with Parkinson’s disease and age-
matched controls. Parkinsonism & Related Disorders 32:66–72. DOI: https://doi.org/10.1016/j.parkreldis.2016.
08.019, PMID: 27591074
Van Den Berge N, Ferreira N, Gram H, Mikkelsen TW, Alstrup AKO, Casadei N, Tsung-Pin P, Riess O,
Nyengaard JR, Tamgu¨ney G, Jensen PH, Borghammer P. 2019. Evidence for bidirectional and trans-synaptic
parasympathetic and sympathetic propagation of alpha-synuclein in rats. Acta Neuropathologica 138:535–550.
DOI: https://doi.org/10.1007/s00401-019-02040-w, PMID: 31254094
Verbaan D, Marinus J, Visser M, van Rooden SM, Stiggelbout AM, van Hilten JJ. 2007. Patient-reported
autonomic symptoms in parkinson disease. Neurology 69:333–341. DOI: https://doi.org/10.1212/01.wnl.
0000266593.50534.e8, PMID: 17646625
Vidakovic L, Singh PK, Hartmann R, Nadell CD, Drescher K. 2018. Dynamic biofilm architecture confers individual
and collective mechanisms of viral protection. Nature Microbiology 3:26–31. DOI: https://doi.org/10.1038/
s41564-017-0050-1, PMID: 29085075
Vuong HE, Yano JM, Fung TC, Hsiao EY. 2017. The microbiome and host behavior. Annual Review of
Neuroscience 40:21–49. DOI: https://doi.org/10.1146/annurev-neuro-072116-031347, PMID: 28301775
Wang L, Magen I, Yuan PQ, Subramaniam SR, Richter F, Chesselet MF, Tache´ Y. 2012. Mice overexpressing wild-
type human alpha-synuclein display alterations in colonic myenteric ganglia and defecation.
Neurogastroenterology & Motility 24:e425–e436. DOI: https://doi.org/10.1111/j.1365-2982.2012.01974.x,
PMID: 22779732
Wang X, Chapman MR. 2008. Sequence determinants of bacterial amyloid formation. Journal of Molecular
Biology 380:570–580. DOI: https://doi.org/10.1016/j.jmb.2008.05.019, PMID: 18565345
Woerman AL, Sto¨hr J, Aoyagi A, Rampersaud R, Krejciova Z, Watts JC, Ohyama T, Patel S, Widjaja K, Oehler A,
Sanders DW, Diamond MI, Seeley WW, Middleton LT, Gentleman SM, Mordes DA, Su¨dhof TC, Giles K, Prusiner
SB. 2015. Propagation of prions causing synucleinopathies in cultured cells. PNAS 112:E4949–E4958.
DOI: https://doi.org/10.1073/pnas.1513426112, PMID: 26286986
Zhang J, Saur T, Duke AN, Grant SG, Platt DM, Rowlett JK, Isacson O, Yao WD. 2014. Motor impairments,
striatal degeneration, and altered dopamine-glutamate interplay in mice lacking PSD-95. Journal of
Neurogenetics 28:98–111. DOI: https://doi.org/10.3109/01677063.2014.892486, PMID: 24702501
Zhou Y, Smith DR, Hufnagel DA, Chapman MR. 2013. Experimental manipulation of the microbial functional
amyloid called curli. Methods in Molecular Biology 966:53–75. DOI: https://doi.org/10.1007/978-1-62703-245-
2_4, PMID: 23299728
Sampson et al. eLife 2020;9:e53111. DOI: https://doi.org/10.7554/eLife.53111 19 of 19
Research article Microbiology and Infectious Disease Neuroscience
